Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Prior treatment

• Previous history of allogeneic hematopoietic stem cell transplantation or organ transplantation (except corneal transplantation).
• Use of immunosuppressive drugs within 14 days prior to treatment, excluding nasal spray and inhaled corticosteroids or physiological doses of systemic steroids (i.e., not more than 10 mg/ day of prednisolone or another corticosteroid at the physiological dose of the drug).
• Arterial or venous thromboembolic events within the previous 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein embolism or any other major thromboembolism, implantable venous access port or catheter-derived thrombosis, or superficial venous thrombosis. Except for patients with stable thrombus after conventional anticoagulant therapy, prophylactic use of low-dose low molecular weight heparin was allowed.
• Previous history of gastrointestinal perforation, gastrointestinal fistula, genital fistula (such as vesicovaginal fistula, urethrovaginal fistula, vesicovaginal fistula, etc.); Patients were allowed if the perforation or fistula had been treated with diversion surgery, resection, or repair, and the disease was recovered or relieved as judged by the investigator.
• Active pulmonary tuberculosis, receiving anti-tuberculosis treatment.
• Severe infections that are active or poorly controlled clinically. Severe infection within 3 weeks before treatment, including but not limited to patients hospitalized for complications of infection, bacteremia, or severe pneumonia.
• Have received live vaccine within 4 weeks of the first use of the experimental drug, or plan to receive live vaccine during the study.

Other illness

• Patients with active autoimmune disease or a history of autoimmune disease.
• Symptomatic congestive heart failure (New York Heart Association class II-IV) Arrhythmias with poorly controlled symptoms.
• Interstitial lung disease.
• Central nervous system metastasis, leptomeningeal metastasis, spinal cord compression, or leptomeningeal disease.
• Human immunodeficiency virus (HIV) infection, known syphilis infection.
• Known or suspected allergy to the trial drug or any drug related to the trial.
• There were other conditions deemed by the investigator to be inappropriate for enrollment.

Lab values

• Previous treatment with anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, or anti-lymphocyte antigen 4 (CTLA-4) antibody.

Other

• Pregnant or lactating women.

• Voluntary participation in clinical research.
• Age ≥18 years old, female.
• Squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix confirmed by histology/cytology.
• Previously untreated locally advancedcervical cancer (2018 FIGO stage IB3, IIA2) .
• At least one measurable lesion was suitable for target lesion according to RECIST v1.1 .
• Within 14 days before the first treatment, the major organ functions were basically normal.
• Eastern Cooperative Oncology Group (ECOG) performance status score 0-1;
• Subjects agree to provide sufficient tumor tissue samples for PD-L1 expression detection;
• If hepatitis B surface antigen (HBsAg) is positive and/or hepatitis B core antibody (HBcAb) is positive, hepatitis B virus DNA (HBV DNA) is detected, HBV DNA \< 104 copies /ml or \< 2000IU/mL can be enrolled. Or those who had received antiviral therapy for at least 4 weeks before the first dose of study drug and were willing to continue antiviral therapy during the study were eligible for enrollment. Those with HCV antibody positive should be excluded.
• Subjects of childbearing age and their sexual partners agreed to consent to contraceptive use after signing an informed consent form, during treatment and for at least 6 months after the last dose of the study intervention.